Matthew Harrison
Stock Analyst at Morgan Stanley
(3.52)
# 804
Out of 5,182 analysts
711
Total ratings
50.23%
Success rate
4.39%
Average return
Main Sectors:
Stocks Rated by Matthew Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Equal-Weight | $769 → $796 | $731.77 | +8.78% | 60 | Apr 10, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $171 → $175 | $129.26 | +35.39% | 45 | Apr 10, 2026 | |
| BIIB Biogen | Maintains: Equal-Weight | $190 → $200 | $183.38 | +9.06% | 57 | Apr 10, 2026 | |
| INSM Insmed | Upgrades: Overweight | $166 → $212 | $134.94 | +57.11% | 21 | Mar 30, 2026 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $40 → $42 | $20.06 | +109.37% | 14 | Mar 26, 2026 | |
| LEGN Legend Biotech | Maintains: Overweight | $50 → $49 | $23.56 | +107.98% | 15 | Mar 11, 2026 | |
| R Ryder System | Maintains: Positive | $235 → $250 | $247.71 | +0.92% | 2 | Feb 13, 2026 | |
| MRNA Moderna | Maintains: Equal-Weight | $30 → $28 | $47.14 | -40.60% | 27 | Dec 12, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $1,070 → $1,110 | $775.03 | +43.22% | 27 | Dec 4, 2025 | |
| PHVS Pharvaris | Maintains: Overweight | $37 → $41 | $28.22 | +45.29% | 16 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $4 | $4.05 | -1.23% | 5 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $98 | $53.30 | +83.86% | 23 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $460 → $439 | $430.14 | +2.06% | 41 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $20 | $21.07 | -5.08% | 38 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6.2 → $6 | $5.58 | +7.53% | 10 | Apr 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $5 | $0.69 | +623.59% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $56 | $36.87 | +51.89% | 2 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $57 → $55 | $27.64 | +98.99% | 2 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $3 | $2.39 | +25.52% | 10 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $39.46 | -72.12% | 9 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 | $3.06 | +128.76% | 18 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $32 | $26.79 | +19.45% | 27 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $21 → $19 | $3.69 | +414.91% | 3 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $2 → $1 | $1.38 | -27.54% | 3 | Mar 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $10 | $23.69 | -57.79% | 9 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $27 → $8 | $7.44 | +7.53% | 9 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $57 → $44 | $28.43 | +54.77% | 28 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $13 | $3.35 | +288.06% | 3 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $80 | $21.48 | +272.53% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $60 | $4.84 | +1,139.67% | 4 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $203 → $216 | $102.06 | +111.64% | 8 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $3.77 | +32.63% | 13 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $3.51 | +42.45% | 6 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $178 → $182 | $197.69 | -7.94% | 8 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $9 | $45.43 | -80.19% | 13 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $279 → $282 | $339.57 | -16.95% | 38 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $220 → $210 | $302.11 | -30.49% | 7 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $55 → $52 | $26.48 | +96.37% | 5 | May 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $175 → $173 | $227.79 | -24.05% | 3 | Apr 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $156 → $120 | $24.53 | +389.20% | 17 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $145 → $148 | $9.61 | +1,440.06% | 19 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $82 | $110.03 | -25.47% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $71 → $66 | $58.26 | +13.29% | 4 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $43 → $39 | $6.30 | +519.05% | 4 | Aug 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $51 → $46 | $49.54 | -7.15% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $33 → $35 | $13.32 | +162.76% | 1 | Aug 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $207 → $275 | $874.00 | -68.54% | 2 | Aug 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $2.83 | +571.38% | 1 | Jun 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $62 | $8.69 | +613.46% | 12 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $17 | $16.55 | +4.23% | 3 | Feb 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $89 → $83 | $97.74 | -15.08% | 1 | Jan 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $10 | $60.69 | -83.52% | 4 | Sep 10, 2018 |
Regeneron Pharmaceuticals
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $769 → $796
Current: $731.77
Upside: +8.78%
Gilead Sciences
Apr 10, 2026
Maintains: Overweight
Price Target: $171 → $175
Current: $129.26
Upside: +35.39%
Biogen
Apr 10, 2026
Maintains: Equal-Weight
Price Target: $190 → $200
Current: $183.38
Upside: +9.06%
Insmed
Mar 30, 2026
Upgrades: Overweight
Price Target: $166 → $212
Current: $134.94
Upside: +57.11%
Denali Therapeutics
Mar 26, 2026
Maintains: Overweight
Price Target: $40 → $42
Current: $20.06
Upside: +109.37%
Legend Biotech
Mar 11, 2026
Maintains: Overweight
Price Target: $50 → $49
Current: $23.56
Upside: +107.98%
Ryder System
Feb 13, 2026
Maintains: Positive
Price Target: $235 → $250
Current: $247.71
Upside: +0.92%
Moderna
Dec 12, 2025
Maintains: Equal-Weight
Price Target: $30 → $28
Current: $47.14
Upside: -40.60%
argenx SE
Dec 4, 2025
Maintains: Overweight
Price Target: $1,070 → $1,110
Current: $775.03
Upside: +43.22%
Pharvaris
Dec 4, 2025
Maintains: Overweight
Price Target: $37 → $41
Current: $28.22
Upside: +45.29%
Nov 12, 2025
Maintains: Equal-Weight
Price Target: $8 → $4
Current: $4.05
Upside: -1.23%
Oct 28, 2025
Maintains: Overweight
Price Target: $104 → $98
Current: $53.30
Upside: +83.86%
Aug 5, 2025
Maintains: Equal-Weight
Price Target: $460 → $439
Current: $430.14
Upside: +2.06%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $15 → $20
Current: $21.07
Upside: -5.08%
Apr 11, 2025
Maintains: Equal-Weight
Price Target: $6.2 → $6
Current: $5.58
Upside: +7.53%
Mar 12, 2025
Maintains: Overweight
Price Target: $15 → $5
Current: $0.69
Upside: +623.59%
Feb 18, 2025
Upgrades: Buy
Price Target: $56
Current: $36.87
Upside: +51.89%
Jan 31, 2025
Maintains: Buy
Price Target: $57 → $55
Current: $27.64
Upside: +98.99%
Nov 26, 2024
Downgrades: Underweight
Price Target: $10 → $3
Current: $2.39
Upside: +25.52%
Jun 21, 2024
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $39.46
Upside: -72.12%
May 9, 2024
Upgrades: Equal-Weight
Price Target: $7
Current: $3.06
Upside: +128.76%
Mar 26, 2024
Maintains: Underweight
Price Target: $32
Current: $26.79
Upside: +19.45%
Aug 14, 2023
Maintains: Equal-Weight
Price Target: $21 → $19
Current: $3.69
Upside: +414.91%
Mar 27, 2023
Maintains: Underweight
Price Target: $2 → $1
Current: $1.38
Upside: -27.54%
Mar 3, 2023
Maintains: Underweight
Price Target: $13 → $10
Current: $23.69
Upside: -57.79%
Feb 28, 2023
Downgrades: Equal-Weight
Price Target: $27 → $8
Current: $7.44
Upside: +7.53%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $57 → $44
Current: $28.43
Upside: +54.77%
Jan 24, 2023
Maintains: Overweight
Price Target: $15 → $13
Current: $3.35
Upside: +288.06%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $140 → $80
Current: $21.48
Upside: +272.53%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $100 → $60
Current: $4.84
Upside: +1,139.67%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $203 → $216
Current: $102.06
Upside: +111.64%
Jan 24, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $3.77
Upside: +32.63%
Jan 24, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $3.51
Upside: +42.45%
Dec 6, 2022
Maintains: Overweight
Price Target: $178 → $182
Current: $197.69
Upside: -7.94%
Nov 14, 2022
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $45.43
Upside: -80.19%
Nov 4, 2022
Maintains: Overweight
Price Target: $279 → $282
Current: $339.57
Upside: -16.95%
Oct 28, 2022
Maintains: Equal-Weight
Price Target: $220 → $210
Current: $302.11
Upside: -30.49%
May 4, 2022
Maintains: Equal-Weight
Price Target: $55 → $52
Current: $26.48
Upside: +96.37%
Apr 6, 2022
Maintains: Equal-Weight
Price Target: $175 → $173
Current: $227.79
Upside: -24.05%
Feb 1, 2022
Maintains: Overweight
Price Target: $156 → $120
Current: $24.53
Upside: +389.20%
Jan 7, 2022
Maintains: Equal-Weight
Price Target: $145 → $148
Current: $9.61
Upside: +1,440.06%
Nov 29, 2021
Maintains: Equal-Weight
Price Target: $88 → $82
Current: $110.03
Upside: -25.47%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $71 → $66
Current: $58.26
Upside: +13.29%
Aug 18, 2021
Maintains: Overweight
Price Target: $43 → $39
Current: $6.30
Upside: +519.05%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $51 → $46
Current: $49.54
Upside: -7.15%
Aug 16, 2021
Maintains: Equal-Weight
Price Target: $33 → $35
Current: $13.32
Upside: +162.76%
Aug 5, 2021
Maintains: Overweight
Price Target: $207 → $275
Current: $874.00
Upside: -68.54%
Jun 24, 2021
Initiates: Buy
Price Target: $19
Current: $2.83
Upside: +571.38%
Mar 8, 2021
Maintains: Overweight
Price Target: $67 → $62
Current: $8.69
Upside: +613.46%
Feb 24, 2021
Maintains: Equal-Weight
Price Target: $16 → $17
Current: $16.55
Upside: +4.23%
Jan 6, 2020
Maintains: Equal-Weight
Price Target: $89 → $83
Current: $97.74
Upside: -15.08%
Sep 10, 2018
Assumes: Equal-Weight
Price Target: $10
Current: $60.69
Upside: -83.52%